The role of octreotide in preventing complications after pancreatoduodenectomy for cancer

HPB

Volumn 2, Issue 3, 2000, Pages 299-312

  Andren Sandberg A ^a   Flati, G ^a   Buchler M ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Anastomotic leakage; Octreotide; Pancreatic fistula; Pancreatic surgery; Pancreatoduodenectomy

Indexed keywords

OCTREOTIDE; PANCREAS ENZYME; SOMATOSTATIN DERIVATIVE;

ANASTOMOSIS LEAKAGE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM CANCER; DRUG INHIBITION; GASTROINTESTINAL TRACT; HUMAN; META ANALYSIS; MULTICENTER STUDY; PANCREAS; PANCREAS FISTULA; PANCREAS SECRETION; PANCREATICODUODENECTOMY; PARENCHYMA; POSTOPERATIVE COMPLICATION; PREOPERATIVE RADIOTHERAPY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK; SURGICAL MORTALITY; SURGICAL TECHNIQUE;

EID: 0034471765     PISSN: 1365182X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1365-182X(17)30750-5     Document Type: Review

References (133)

1. Das Carcinom der Papilla duodeni und seine radikale Entfernung
2. Treatment of carcinoma of the ampulla of Vater
3. Reoperations for pancreatic cancer
4. Factors influencing survival after total pancreatectomy in patients with pancreatic cancer
5. Relation of preoperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy
6. The advantages of bypass operations over radical pancreatoduodenectomy in the treatment of pancreatic carcinoma
7. Adenocarcinoma of the pancreas: A statistical analysis of biliary bypass vs Whipple resection in good risk patients
8. Presidential address: Natural selection in university surgery
9. Pancreatico-duodenectomy: Forty-one consecutive Whipple resections without an operative mortality
10. The surgical treatment of pancreatic carcinoma
11. Pankreasganganastomose und Pankreatojejunoplacation nach Rechtsresektion
12. Pyloric preservation with the Whipple Procedure
13. Decreased morbidity and mortality after pancreatoduodenectomy
14. Pyloric and gastric preserving pancreatic resection: Experience with 87 patients
15. Improved hospital morbidity, mortality, and survival after the Whipple procedure
16. An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomy
17. Resectional surgical procedures for carcinoma of the head of the pancreas
18. Survival after pancreatico-duodenectomy: 118 consecutive resections without an operative mortality
19. Resection for cancer of the pancreas - The Japanese experience
20. Complications following pancreaticoduodenectomy. Current management
21. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality
22. Complications and outcome in the treatment of pancreatic adenocarcinoma in the United States veteran
23. Surgical treatment of pancreatic cancer
24. Pancreatic resection for carcinoma of the pancreas: Whipple versus total pancreatectomy - An institutional perspective
25. Surgery for periampullary and pancreatic carcinoma: A Liverpool experience
26. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes
27. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. UK Pancreatic Cancer Group
28. Resection of pancreatic cancer - Surgical achievements
29. Factors influencing morbidity and mortality after pancreaticoduodenectomy: Critical analysis of 221 resections
30. Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database
31. Role of octreotide in the prevention of postoperative complications following pancreatic resection
32. Efficacy of octreotide in the prevention of complications of elective pancreatic surgery
33. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy
34. Optimal management of the pancreatic remnant after pancreaticoduodenectomy
35. Pancreatic anastomotic leak after pancreaticoduodenectomy: Incidence, significance, and management
36. Prognostic indicators for survival after resection of pancreatic adenocarcinoma
37. Standards for pancreatic resection in 1990s
38. Pancreas cancer resection outcome in American University centers in 1989-1990
39. A prospective cost analysis of pancreaticoduodenectomy
40. Standard Kausch-Whipple pancreatoduodenectomy
41. A surgical and pathological based classification on resective treatment of pancreatic cancer
42. Treatment and survival in 13540 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study
43. Surgery for pancreatic cancer
44. Surgical treatment of pancreatic cancer
45. Management of complications following pancreaticoduodenectomy
46. Considerations that lower pancreatoduodenectomy mortality
47. Results of radical resection for periampullary cancer
48. Characteristics of the gland remnant predict complications after subtotal pancreatectomy
49. Pancreatic juice output after pancreaticoduodenectomy in relation to pancreatic consistency, duct size, and leakage
50. Cancer of the pancreas: Palliative operation, Whipple procedure, or total pancreatectomy?
51. Concomitant benefit in preventing pancreatic fistula formation after pancreaticoduodenectomy
52. Attempted curative resection of ductal carcinoma of the pancreas. Review of Mayo Clinic experience, 1951-1975
53. Pancreatic cancer in 1988. Possibilities and probabilities
54. The disintegration of surgical sutures on exposure to pancreatic juice
55. Progress in reconstruction after resection of the head of the pancreas
56. Are pancreatoenteric anastomoses improved by duct-to-mucosa sutures?
57. Pancreatoduodenectomy with pylorus preservation for adenocarcinoma of the head of the pancreas
58. Successful pancreaticojejunal anastomosis for pancreaticoduodenectomy
59. A secured technique for pancreatojejunal anastomosis in pancreaticoduodenectomy
60. Protection of pancreatic and biliary anastomosis after partial duodenopancreatectomy by external drainage
61. Duct to mucosa isolated Roux loop pancreaticojejunostomy as an improved anastomosis after resection of the pancreas
62. A method for safe pancreaticojejunostomy
63. New technique for pancreaticojejunostomy using a biological adhesive
64. Fibrin glue sealing of pancreatic injuries, resections and anastomoses
65. Pancreaticoduodenectomy with occlusion of the residual stump by Neoprene injection
66. Second-stage pancreaticojejunostomy following pancreaticoduodenectomy in high-risk patients
67. Subtotal duodeno-pancreatectomy for carcinoma of the head of the pancreas. Preliminary report of an alternative operation to total pancreatectomy
68. Pancreaticojejunostomy versus controlled pancreaticocutaneous fistula in pancreaticoduodenectomy for periampullary carcinoma
69. Treatment of pancreatic cutaneous fistula with a somatostatin analogue
70. Conservative treatment of external pancreatic fistulas with parenteral nutrition alone or in combination with continuous intravenous infusions of somatostatin, glucagon or calcitonin
71. Blind evaluation of the effect of octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output
72. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: A prospective, controlled, randomized clinical trial
73. Somatostatin for the prevention of complications following pancreaticoduodenectomy
74. Morbidity and mortality after radical and palliative pancreatic cancer surgery. Risk factors influencing the short-term results
75. Pancreatic fistula and relative mortality in malignant disease after pancreaticoduodenectomy. Review and statistical meta-analysis regarding 15 years of literature
76. The risk of pancreaticointestinal anastomosis can be predicted pre-operatively
77. Prevention and treatment of complications in pancreatic cancer surgery
78. Preoperative exocrine pancreatic function predicts risk of leakage of pancreaticojejunostomy
79. Risk analysis of pancreatic fistula after pancreatic head resection
80. Considerations that lower pancreatoduodenectomy mortality
81. Factors influencing morbidity and mortality in pancreaticoduodenectomy
82. The complications of pancreatectomy
83. Completion pancreatectomy following pancreaticoduodenectomy. Clinical experience
84. Completion pancreatectomy for surgical complications after pancreaticoduodenectomy
85. Arterial hemorrhage after pancreaticoduodenectomy. The 'sentinel bleed'
86. Experimental transplantation of the pancreas into the stomach
87. The relative effectiveness of somatostatin and octreotide therapy in pancreatic disease
88. Role of somatostatin and somatostatin analogues in the treatment of gastrointestinal disease: Prevention of complications after pancreatic surgery
89. Pancreaticoduodenal resection
90. Management of the pancreas after pancreaticoduodenectomy
91. Pancreatic fistula complicating pancreatectomy for malignant disease
92. Pancreaticoduodenal resection for pancreatic or periampullary tumours: A ten-year experience
93. Factors influencing morbidity and mortality in pancreaticoduodenectomy
94. Fistules pancréatiques post-operatoires: Étude clinique sur un serie de 114 duodeno-pancréatectomies céphaliques consécutives
95. Octreotide for treatment of postoperative alimentary tract fistulas
96. Somatostatin in the management of gastrointestinal fistulas. A multicenter trial
97. Randomized double-blind placebo-controlled trial of early octreotide in patients with postoperative enterocutaneous fistula
98. Effect of octreotide acetate on pancreatic exocrine function
99. Inhibition of exocrine pancreatic secretion by somatostatin and its analogues
100. Effects of somatostatin on the exocrine pancreas and the release of duodenal hormones
101. Inhibition by somatostatin of pancreatic juice and enzyme secretion and gallbladder contraction in man induced by secretin and cholecysto-pancreozymin administration
102. Somatostatin analogs: Correlation of receptor affinity with inhibition of cyclic AMP formation in pancreatic acinar cells
103. Effect of somatostatin in plasma amino acid uptake by human pancreas
104. Prevention of postoperative pancreatic complications following duodenopancreatectomy using somatostatin
105. Effect of octreotide acetat on pancreatic exocrine and endocrine functions after pancreatoduodenal resection
106. The influence of somatostatin on postoperative outcome after elective pancreatic surgery
107. Effect of a new somatostatin analogue on pancreatic function in healthy volunteers
108. Inhibition of human exocrine pancreatic secretion by the long-acting somatostatin analogue octreotide (SMS 201-995)
109. Effect of the somatostatin analogue Sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men
110. Effect of somatostatin analogue (SMS 201-995, Sandostatin) on pancreatic secretion in humans
111. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
112. Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin
113. Effect of octreotide (SMS 201-995) on exocrine pancreatic function in man
114. Is octreotide a new hope for enterocutaneous and external pancreatic fistula closure?
115. Inhibition of pancreatic secretion under long-term octreotide treatment in humans
116. Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies
117. Clinical pancreas transplantation: A learning curve of its management
118. Effects of lanreotide, a somastostatin analogue, on post-prandial gastric functions and biliopancreatic secretions in humans
119. A prospective, randomized trial using octreotide in the prevention of post-operative complications following pancreaticoduodenal resections
120. Place de l'octréotide dans la prévention des complicationes chirurgicales après pancreatectomie. Etude controlée multicentrique
121. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease
122. Randomized, controlled multicenter study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis
123. Economic evaluation of the use of octreotide for prevention of complications following pancreatic resection
124. Octreotide and postoperative enterocutaneous fistulae: A controlled prospective study
125. Prevention of postoperative complication following pancreatic surgery
126. Prophylaxis of complications after pancreatic surgery: Results of a multicenter trial in Germany
127. Inhibition of pancreatic secretion to prevent postoperative complications following pancreatic resection
128. Prophylaxis of complications after pancreatic surgery: Results of a multicenter trial in Italy
129. The role of somatostatin and octreotide in pancreatic surgery and in acute and chronic pancreatitis
130. The use of octreotide to prevent postoperative complications after major pancreatic resection
131. Common difficulties and complications in pancreatic surgery
132. Management of digestive tract fistulas
133. Randomized double-blind placebo-controlled trial of early octreotide in patients with postoperative enterocutaneous fistula